Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

1.22
-0.0300-2.40%
Post-market: 1.17-0.0499-4.09%19:51 EST
Volume:106.84K
Turnover:133.51K
Market Cap:7.62M
PE:-0.19
High:1.34
Open:1.26
Low:1.18
Close:1.25
52wk High:13.69
52wk Low:1.18
Shares:6.24M
Float Shares:3.77M
Volume Ratio:1.14
T/O Rate:2.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.3682
EPS(LYR):-2.4500
ROE:-159.46%
ROA:-57.76%
PB:0.67
PE(LYR):-0.50

Loading ...

Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)

TIPRANKS
·
Aug 07

Oculis Q2 Net Loss Narrows Despite Higher Expenses

Reuters
·
Aug 07

Aligos Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate

Benzinga Earnings
·
Aug 06

Aligos Q2 FY26 Net Loss Narrows 91% to $1.5 Million

Reuters
·
Aug 06

Aligos Therapeutics Q2 EPS USD -0.14

THOMSON REUTERS
·
Aug 06

Aligos Therapeutics Q2 Operating Expenses USD 29.668 Million

THOMSON REUTERS
·
Aug 06

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

GlobeNewswire
·
Aug 06

Aligos Therapeutics, Inc. Expected to Post a Loss of $1.07 a Share - Earnings Preview

Reuters
·
Aug 04

Aligos Therapeutics Inc Expected to Post a Loss of $1.07 a Share - Earnings Preview

Reuters
·
Jul 31

Aligos Therapeutics to Report Q2 2026 Financial Results

Reuters
·
Jul 30

Analyst Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target Amid Strengthened HBV Trial Outlook

TIPRANKS
·
Jul 14

Aligos Completes Enrollment in Phase 2 B-supreme Trial for Chronic Hepatitis B Drug Pevifoscorvir Sodium

Reuters
·
Jul 13

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-supreme Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic Hbv Infection

THOMSON REUTERS
·
Jul 13

Aligos Therapeutics - Topline Safety and Efficacy Data Expected in Late Q3 2027

THOMSON REUTERS
·
Jul 13

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

GlobeNewswire
·
Jul 13

Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech

Dow Jones
·
Jul 07

Aligos Rises on Receiving Upfront Payment from Hepatitis B Drug License Deal

Reuters
·
Jul 07

Aligos Therapeutics receives $25M upfront for pevifoscorvir sodium license deal

TIPRANKS
·
Jul 07

Aligos Therapeutics Receives USD 25 Million Upfront in Greater China Pevifoscorvir License Deal with Amoytop

Reuters
·
Jul 07